DURECT TO PRESENT CLINICAL DATA AT UPCOMING CONFERENCE

Durect plans to present preliminary cohort 3 clinical data from its Phase II study for its postoperative pain relief depot, SABER-Bupivacaine, during the upcoming American College of Surgeons Conference in San Francisco, Calif.

Durect recently announced the completion of dosing in the third and final cohort of the Phase II dose-escalation study in hernia patients in Australia for SABER-Bupivacaine. The company completed enrollment of 60 patients in cohort 3, which will be presented in conjunction with cohort 1 and cohort 2 data. SABER-Bupivacaine is based on Durect's patented SABER delivery technology, and is intended to be administered around the surgical site after surgery to provide three days or more of local analgesia.